At a glance
ClinicalIndex Comparison RecordN/ACompleted· 115 enrolled
Drug / intervention
intravitreal injection of Ranibizumabdrug
Likely dose
intravitreal injection of Ranibizumab 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Outcome Following Reinjection of Ranibizumab in Recurrent Cases With Retinopathy of Prematurity
In Brief
An observational study evaluating intravitreal injection of Ranibizumab for Retinopathy of Prematurity. Completed, enrolled 115 participants across 1 site.
Detailed Summary
A retrospective study included reviewing of medical records of preterm babies who were admitted in neonatal intensive care unit (NICU) of Mansoura University children hospital (MUCH) or referred from nearby hospitals for ROP screening during the period from March 2013 to February 2020.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRetinopathy of Prematurity
CountriesEgypt
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
Primary CompletionFeb 2020
First PostedSep 2020
TodayJul 2026
First PostedSep 4, 2020
Enrollment StartJun 1, 2019
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.8 years ago
Interventions
intravitreal injection of Ranibizumabdrug
intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus